| Julia L Oh, MD | |
|
15500 Southwest Fwy, Sugar Land, TX 77478-3829 | |
| (281) 274-8200 | |
| (281) 584-7436 |
| Full Name | Julia L Oh |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 25 Years |
| Location | 15500 Southwest Fwy, Sugar Land, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902901796 | NPI | - | NPPES |
| 168320301 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | M1991 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hca Houston Healthcare West | Houston, TX | Hospital |
| Entity Name | West Houston Internal Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1730471871 PECOS PAC ID: 3779751490 Enrollment ID: O20110725000665 |
News Archive
New technology is bringing the power of augmented reality into clinical practice.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has signed a letter of agreement with Viropro, Inc., for the development of a biosimilar version of the monoclonal antibody drug rituximab (marketed by Genentech/Roche). Worldwide sales of rituximab in 2009 in all indications, including non-Hodgkin's lymphoma and chronic lymphocytic lymphoma, were approximately $5.6 billion.
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. The trial was initiated in 2009 and was a proof-of-concept, open-label study in children 6 to 12 years of age, assigned to one of four doses over a six-week treatment period, after 2-5 weeks' titration.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julia L Oh, MD 15500 Southwest Fwy, Sugar Land, TX 77478-3829 Ph: (281) 274-8200 | Julia L Oh, MD 15500 Southwest Fwy, Sugar Land, TX 77478-3829 Ph: (281) 274-8200 |
News Archive
New technology is bringing the power of augmented reality into clinical practice.
Taro Pharmaceutical Industries Ltd. reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Granisetron Hydrochloride Tablets USP, 1 mg (base) ("granisetron tablets").
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has signed a letter of agreement with Viropro, Inc., for the development of a biosimilar version of the monoclonal antibody drug rituximab (marketed by Genentech/Roche). Worldwide sales of rituximab in 2009 in all indications, including non-Hodgkin's lymphoma and chronic lymphocytic lymphoma, were approximately $5.6 billion.
CSL Behring today presented data from a Phase I/III study on the efficacy and safety of its novel investigational recombinant factor VIII single chain in adolescents and adults with hemophilia A during a late breaking abstract session at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress.
Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. The trial was initiated in 2009 and was a proof-of-concept, open-label study in children 6 to 12 years of age, assigned to one of four doses over a six-week treatment period, after 2-5 weeks' titration.
› Verified 6 days ago
Nooruddin S Punjwani, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 515 Olmstead Park Dr, Sugar Land, TX 77479 Phone: 303-933-8270 | |
Megan Jenkins Kalambo, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 17510 W Grand Pkwy S, Sutie 120, Sugar Land, TX 77479 Phone: 713-745-4555 Fax: 713-563-9779 | |
Yuxuan Lin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5231 Fountainbrook Ln, Sugar Land, TX 77479 Phone: 713-443-8571 | |
Dr. Carlos R Hamilton Iii, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4690 Sweetwater Blvd, Suite 200, Sugar Land, TX 77479 Phone: 281-565-0033 Fax: 281-565-0568 | |
Puneet Ghei, MD Radiology Medicare: Medicare Enrolled Practice Location: 1435 Highway 6 Ste 102, Sugar Land, TX 77478 Phone: 281-313-1700 Fax: 281-313-1705 | |
Judson Horace Snow Jr., M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 17500 W Grand Pkwy, Sugar Land, TX 77479 Phone: 713-481-3533 Fax: 713-432-0221 | |
Dr. John H. Fischer Ii, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4690 Sweetwater Blvd Ste 200, Sugar Land, TX 77479 Phone: 281-565-0033 Fax: 281-565-0568 |